Long-term results of radiotherapy for non-melanoma skin cancer on the head and neck
Looks at how skin looks and heals years after radiotherapy for skin cancer.
Plain-language title generated from the registry record
Registry title: The Role of Radiotherapy for the Management of Non-melanoma Skin Cancer in Denmark.
Key facts
- Where
- Aarhus N, DenmarkSee the site
Where in Denmark
- Aarhus University HospitalAarhus N, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT07347392
- Record updated
- 16 January 2026
- Original description
The goal of this observational study is to learn about the long-term effects of radiotherapy for people who were treated for non-melanoma skin cancer (NMSC) in the head and neck area. The study focuses on adults who finished radiotherapy at least two years ago.Read full original descriptionShow less
The Role of Radiotherapy for the Management of Non-melanoma Skin Cancer in Denmark
The goal of this observational study is to learn about the long-term effects of radiotherapy for people who were treated for non-melanoma skin cancer (NMSC) in the head and neck area. The study focuses on adults who finished radiotherapy at least two years ago.
The main questions we aim to answer are:
How satisfied are participants with the cosmetic result of their treatment?
What skin changes do healthcare professionals observe at the treated area?
How many participants have experienced a recurrence or developed a new skin cancer, since treatment?
Participants will be invited to:
Attend one extra hospital visit at least two years after they finished radiotherapy
Answer a short questionnaire about their cosmetic satisfaction
Have their skin examined, including photos and dermatoscopy
The results may help improve future treatment guidelines for people with non-melanoma skin cancer.professional, and any local recurrences will be identified through national health registries.
This nationwide study (DOSCA-2) will provide real-world data to help guide future treatment recommendations for NMSC.
Inclusion: Adults aged 18 years or older; Received primary radiotherapy for malignant non-melanoma skin cancer (basal cell carcinoma or cutaneous squamous cell carcinoma) of the head and neck region between 2020 and 2024; Able to understand and communicate in written and spoken Danish or English.
Exclusion: Individuals who are incapable of giving informed consent.